San Francisco, CA, May 31, 2010–A single pre-operative intravesical electromotive (EMDA) instillation of mitomycin-C (MMC) improves a patient’s risk of non-muscle invasive bladder cancer (NMIBC) recurrence more than a single post-operative intravesical passive instillation, according to new research from investigators in Italy. This preventive measure can also enhance a patient’s disease-free interval. These data will be presented during the 105th Annual Meeting of the American Urological Association (AUA). Members of the media can meet with researchers and hear more during a special press conference on Monday, May 31, 2010 at 9 a.m. PDT.
Researchers from Italy studied 352 patients with NMIBC to compare the effects of two different delivery systems for a chemotherapeutic agent with transurethral resection (TUR) alone (cancerous tissue removal) of the bladder. Patients, randomized into three groups, received either one immediate pre-TUR EMDA/MMC instillation; one early post-operative intravesical passive diffusion (PD) MMC instillation; or TUR without adjuvant therapy. Patients with intermediate and high risk NMIBC underwent adjuvant standard intravesical therapy. After following-up with patients about seven years later, researchers found that cancer recurrence occurred significantly less often in the EMDA/MMC pre-TUR group. This trend was also evident in the overall median disease-free intervals, which were shown to be 12.9 months for the TUR-alone group, 16.4 months for the PD/MMC post-TUR group and 56.9 for the EMDA/ MMC pre-TUR group.
The researchers concluded that in patients with multifocal intermediate and high risk NMIBC, one immediate pre-TUR intravesical EMDA/MMC instillation would decrease the risk of recurrence and enhance disease-free intervals compared to one early post-TUR intravesical PD/MMC instillation or TUR alone.
“Catching bladder cancer before it invades the muscle is key to a patient’s survival,” said Kevin T. McVary, MD, the AUA spokesman who moderated the briefing. “But even with early detection this paper demonstrates that recurrence rates can be reduced by preoperative intravesical EMDA/MMC instillation. Knowing that a pre-operative dose of mitomycin-C can help improve that survival is extremely important.”
NOTE TO REPORTERS: Experts are available to discuss this study outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail Communications@AUAnet.org.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.
Wendy Isett, AUA